Singular Genomics Systems Inc
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. It is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection wit… Read more
Singular Genomics Systems Inc (OMIC) - Total Assets
Latest total assets as of September 2024: $186.55 Million USD
Based on the latest financial reports, Singular Genomics Systems Inc (OMIC) holds total assets worth $186.55 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Singular Genomics Systems Inc - Total Assets Trend (2019–2023)
This chart illustrates how Singular Genomics Systems Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Singular Genomics Systems Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Singular Genomics Systems Inc's total assets of $186.55 Million consist of 72.4% current assets and 27.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.1% |
| Accounts Receivable | $1.58 Million | 0.6% |
| Inventory | $13.57 Million | 5.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2023)
This chart illustrates how Singular Genomics Systems Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Singular Genomics Systems Inc's current assets represent 72.4% of total assets in 2023, a decrease from 96.4% in 2019.
- Cash Position: Cash and equivalents constituted 6.1% of total assets in 2023, down from 11.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 5.1% of total assets.
Singular Genomics Systems Inc Competitors by Total Assets
Key competitors of Singular Genomics Systems Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
|
LKL International Bhd
KLSE:0182
|
Malaysia | RM173.46 Million |
Singular Genomics Systems Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Singular Genomics Systems Inc generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Singular Genomics Systems Inc is currently not profitable relative to its asset base.
Singular Genomics Systems Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.37 | 13.64 | 7.47 |
| Quick Ratio | 6.67 | 12.77 | 7.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $112.20 Million | $ 195.34 Million | $ 23.88 Million |
Singular Genomics Systems Inc - Advanced Valuation Insights
This section examines the relationship between Singular Genomics Systems Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.41 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | -19.1% |
| Total Assets | $265.47 Million |
| Market Capitalization | $36.81 Million USD |
Valuation Analysis
Below Book Valuation: The market values Singular Genomics Systems Inc's assets below their book value (0.14 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Singular Genomics Systems Inc's assets decreased by 19.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Singular Genomics Systems Inc (2019–2023)
The table below shows the annual total assets of Singular Genomics Systems Inc from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $265.47 Million | -19.06% |
| 2022-12-31 | $327.98 Million | -7.78% |
| 2021-12-31 | $355.65 Million | +1065.98% |
| 2020-12-31 | $30.50 Million | -36.68% |
| 2019-12-31 | $48.17 Million | -- |